Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 12 Parkinson's papers of 1,403 | 0.66 |
| pathways Reactome | 6 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 3134
Sealed predictions
- ANXA1 in dopamine neurons, braak+0.12 (p 0.749) → +0.68 (p 0.043)receipt 3141
Swarm cases
receipt 3141: ANXA1 in dopamine neurons, braak
- power
- full sample +0.41 (p 0.087, n 18), 95% CI -0.07 to +0.74. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.38 (p 0.123, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.44 (p 0.067, n 18). could be the mix.
- skeptic
- leave-one-out range +0.34 to +0.57, sign flips 0; without severely affected donors +0.41 (p 0.087, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ANXA1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts